SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following reports of potential partnerships and investments from companies like TSMC and Apple, fueling speculation about its comeback in the semiconductor industry. The community is actively discussing the implications of these developments, particularly in light of potential government mandates favoring domestic chip manufacturing. Bullish sentiment is growing as investors anticipate significant gains and a potential return to prominence for Intel.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining (CIFR) is trending due to the announcement of an upsized convertible bond offering and a related hosting agreement with Fluidstack, backed by Google, leading to significant price volatility. While some investors express concerns about potential dilution, others view the developments as a sign of strong market confidence and a catalyst for growth in mining capacity and high-performance computing. The community is actively debating the long-term implications of the offering and its impact on the stock's trajectory.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crowd with Knife ($CAW.X) is trending as the community buzzes about its deflationary tokenomics and organic, cult-like following. Discussions highlight its multichain functionality across Solana, BSC, CRO, and ETH (BASE), facilitated by Layerzero tech. The built-in burn mechanism on each bridge is also a key talking point.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

LAC is trending as reports circulate that the U.S. government may take a stake in the company, tied to its DOE loan, sparking debate about government involvement in for-profit business. The community is discussing the potential for a short squeeze and comparing it to similar situations with MP Materials and Intel, while also considering the impact on lithium supply chains and national security. Some traders are pointing to technical indicators and overnight trading activity, while others express skepticism about the company's fundamentals and potential dilution.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is gaining traction as a potential successor in the meme coin space, drawing comparisons to $PEPE and other Solana-based tokens. Community members are actively monitoring its chart and volume, emphasizing the ease of access through Phantom Wallet. The focus remains on its potential for significant growth within the broader crypto market.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as the CDC's advisory panel reviews COVID-19 vaccine recommendations, with discussions around potential risks of mRNA vaccines. The community is focused on the potential for Novavax's non-mRNA vaccine to gain market share. Additionally, new import tariffs and recent rollout updates with Sanofi are being closely monitored as potential catalysts.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Despite a recent earnings beat, Costco's stock is trending as the community debates whether the valuation is justified, especially with tariffs looming. Community members are closely watching membership fee revenue and same-store sales data for indications of future performance. The stock's high PE ratio is also a key point of discussion, with some suggesting it's overvalued compared to growth prospects.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax ($KMX) is trending due to disappointing Q2 results, including a slump in car sales and increased loan loss provisions, leading to a breach of its 52-week low. Community discussions revolve around whether the stock is oversold and if it presents a buying opportunity, with some comparing it unfavorably to competitors like Carvana ($CVNA). The broader context involves concerns about the used car market, high interest rates, and potential impacts from tariffs.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending due to FDA approval of their oral acromegaly drug, Palsonify, driving significant retail investor chatter. The community is focused on the potential for a short squeeze given high institutional ownership and short interest, alongside discussions about revenue projections and buyout possibilities. Broader sentiment suggests optimism regarding the drug's market potential and impact on patient care.

Eason Technology Ltd. engages in the provision of loan facilities to micro, small and medium size enterprises, and sole proprietors. It also offers microfinance lending services. The company was founded by Qi Ming Xu and Kang Kai Zeng on June 24, 2010 and is headquartered in Wuhan, China.

Eason Technology Ltd. - ADR

Eason Technology Ltd ADR

Eason Technology Ltd ADR ($DXF) is trending as traders discuss its potential for a significant price movement, pointing to its small float and past rallies. Community members are closely watching for news, particularly regarding the company's compliance filings and potential crypto-related announcements, which they believe could trigger a substantial surge. Some traders are expressing confidence, drawing comparisons to other low-float stocks that have recently experienced rapid gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

British drugmaker GSK Plc (GSK) on Wednesday announced that it now expects full-year earnings and turnover to be toward the top end of its guidance after its second-quarter earnings surpassed Wall Street expectations on strong sales of its specialty medicines.The company now <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf">expects</a> turnover growth to be toward the top end of 3% to 5% and for core earnings per share growth to be closer to 8% at constant exchange rate.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GSK">GSK</a> trended in the ‘bearish’ territory over the past 24 hours, while message volume dropped from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_8_18_14_AM_png_6f597ae2a0.webp" alt="GSK's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 30, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>GSK's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>CEO Emma Walmsley pegged the increase in guidance to another quarter of excellent performance, driven by the company’s specialty medicines segment.“We also continue to make very good progress in research and development, with 3 major FDA approvals achieved so far this year, 16 assets now in late-stage development, and 4 more promising medicines to treat cancer, liver disease and HIV expected to enter Phase III and pivotal development by the end of the year. With all this, we now expect to be towards the top end of our financial guidance for 2025 and remain confident in our long-term outlooks," the CEO said.GSK is eyeing annual sales of over £40 billion ($53.28 billion) by 2031. &nbsp;The company on Wednesday noted that its guidance is inclusive of tariffs enacted by the U.S. thus far and European tariffs indicated this week.“We are positioned to respond to the potential financial impact of tariffs, with mitigation options identified. Given the uncertain external environment, we will continue to monitor developments,” the firm said.For the second quarter, the company reported sales of about £8.00 billion, marking a growth of 6% at constant exchange rate and above an analyst estimate of £7.81 billion, according to data from Fiscal AI.Specialty medicines sales rose 15% to £3.3 billion, thanks to double-digit sales growth in Respiratory, Immunology &amp; Inflammation, Oncology, and HIV drugs at constant exchange rate.Vaccine sales, meanwhile, rose 9% to £2.1 billion while general medicines sales fell 6%.Core earnings per share came in at 46.5 pence in the three months through the end of June, up from an analyst estimate of 42 pence.NYSE-listed shares of GSK are up by over 11% this year but down by over 5% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/humana-announces-upbeat-earnings-raised-guidance/choXGmPR5zr">Humana Stock Gains On Upbeat Earnings And Raised Guidance, Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: £1= $1.33)

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’

GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.

Equity

U.S. Food and Drug Administration reviewers on Tuesday flagged certain concerns about GSK Plc’s (GSK) investigational cancer drug called Blenrep, including a high rate of ocular toxicities.Ocular toxicity refers to the harmful effects a substance or drug has on the eye, potentially causing damage to its structure or impairing its function.<a href="https://stocktwits.com/symbol/GSK">GSK</a> is seeking approval for the drug, also known as Belantamab Mafodotin, in the treatment of adults with multiple myeloma in combination with Bortezomib or Pomalidomide and Dexamethasone in patients who have received at least one prior line of therapy. The application is based on data from two late-stage trials.FDA reviewers <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/media/187578/download">stated</a> in briefing documents on the regulator’s website that the benefit-risk profile of the drug for treating multiple myeloma “remains unclear,” considering efficacy results, safety and tolerability concerns, and uncertainties regarding the appropriateness of the proposed dosages.The documents were released ahead of an advisory committee meeting scheduled for Thursday. The FDA is expected to decide on approving or disapproving the drug by next week.The reviewers noted a high incidence of ocular toxicity with the treatment, including keratopathy (changes in the corneal epithelium), changes in clarity of vision, as well as other ocular symptoms, such as blurred vision and dry eyes.“The ocular toxicity, including corneal toxicity, observed with Belantamab Mafodotin is a unique toxicity that is not seen with any currently available treatments for multiple myeloma,” they said.While ocular toxicity may be asymptomatic in its early stages, it can result in severe consequences, such as loss of vision, the reviewers noted.The agency also expressed concern that the dosages of Belantamab Mafodotin have not been adequately optimized, as evidenced by the high rates of dose modifications in both trials referred to in the application.A majority of patients were not receiving the intended dosage and required frequent dose modifications, including interruptions, throughout the duration of treatment, the agency said.Blenrep was previously granted accelerated approval as monotherapy on Aug. 5, 2020, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. It was subsequently withdrawn on Feb. 6, 2023, due to failure of the confirmatory trial to meet its progression-free survival endpoint.On Stocktwits, retail sentiment about GSK fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_15_at_1_26_26_PM_png_1594f6ef5c.webp" alt="GSK's Sentiment Meter and Message Volume as of 1:25 p.m. ET on July 15, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>GSK's Sentiment Meter and Message Volume as of 1:25 p.m. ET on July 15, 2025 | Source: Stocktwits</figcaption></figure>GSK stock is up 6% this year but down by 4% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-stock-flies-on-expansion-of-marina-site/ch8Q95jR5Fw">Joby Aviation Stock Flies High On Expansion Of Marina Site, Retail Boards The Flight</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US FDA Reviewers Highlight Safety Concerns With GSK’s Investigational Cancer Drug: Retail’s On The Fence

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.”

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the disease has been accepted by the U.S. Food and Drug Administration (FDA).The vaccine is currently approved in the U.S. for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk. Adults can be at increased risk for RSV disease due to certain comorbidities, immune-compromised status, or advanced age.A regulatory decision by the FDA on this submission is <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine/">expected</a> in the first half of 2026.<a href="https://stocktwits.com/symbol/GSK">GSK</a> is continuing to seek expanded indications for its RSV vaccine in other geographies, including in the European Economic Area and Japan, the company said.RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year, as per GSK. RSV can exacerbate conditions, including Chronic Obstructive Pulmonary Disease (COPD), asthma, and chronic heart failure, and can lead to severe outcomes, such as pneumonia, hospitalization, and death.Arexy’s turnover fell 57% in the first quarter (Q1) of 2025 to £78 million ($105 million) due to lower demand. The company pegged the decline in sales within the U.S. partly to a more limited recommendation from the Advisory Committee on Immunization Practices for individuals aged 60 to 74.On Stocktwits, retail sentiment around GSK stayed unmoved within ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_8_31_53_AM_png_fd0d117e35.webp" alt="GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 | Source: Stocktwits" width="1366" height="130"><figcaption>GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>NYSE-listed shares of GSK are up by 13% this year but down by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/synopsys-ansys-35-billion-deal-reportedly-gets-china-conditional-approval/ch8Bx5yR5V8">Synopsys-Ansys’ $35B Deal Reportedly Gets China’s Conditional Approval Days Before Closure Deadline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: £1= $1.35)

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance

A decision by the FDA on the new submission is expected in the first half of 2026.

Fidelity Covington Trust - Fidelity Women's Leadership

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

FDWM
Fidelity Covington Trust - Fidelity Women`s Leadership ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FDWM News

FDWM Fidelity Covington Trust - Fidelity Women`s Leadership ETF